Tivacoma (30 mg Pre-Filled Syringe)
Solution for injection containing tivacoma — prescription medication for subcutaneous administration
Quick Facts About Tivacoma
Key Takeaways About Tivacoma
- Prescription-only injectable: Tivacoma is dispensed only on prescription and must be initiated by a physician with experience in the relevant clinical area.
- Pre-filled, single-use syringe: Each 30 mg pre-filled syringe contains a single dose – do not reuse, share, or refill it.
- Subcutaneous administration: Inject just under the skin into the abdomen or front of the thigh, rotating sites with each injection to limit local reactions.
- Cold-chain storage: Store unopened syringes in a refrigerator at 2°C–8°C in the original carton; do not freeze or shake.
- Report adverse reactions: Contact your healthcare provider promptly if you notice severe injection-site reactions, signs of infection, or symptoms suggestive of a hypersensitivity reaction.
What Is Tivacoma and What Is It Used For?
Tivacoma is a prescription-only medication supplied as a sterile 30 mg solution in a pre-filled syringe. It contains the active substance tivacoma and is given as a subcutaneous injection. Your prescriber will determine when and why Tivacoma is appropriate based on your individual diagnosis, treatment goals, and medical history.
Tivacoma is a parenteral medication, meaning it bypasses the digestive tract and is delivered directly into the body through an injection. Parenteral administration is selected when a medicinal substance is poorly absorbed from the gastrointestinal tract, when it would be degraded by stomach acid or first-pass hepatic metabolism, or when a more predictable and consistent systemic exposure is required for therapeutic effect. The 30 mg pre-filled syringe is designed to deliver an accurately measured single dose, eliminating the dose-calculation errors that can occur when a clinician or patient draws medication from a multi-dose vial.
The active substance in Tivacoma is tivacoma, formulated at a concentration intended to deliver 30 mg per syringe. Each syringe is a single-use device: once the dose has been administered, the syringe and its needle must be discarded into an approved sharps container. Pre-filled syringes are favored in many therapeutic areas because they reduce preparation time, lower the risk of contamination, and are particularly suitable for self-administration once a patient or caregiver has been formally trained.
As with all prescription medicines, Tivacoma has been evaluated by regulatory authorities such as the European Medicines Agency (EMA) and other competent national bodies for quality, safety, and efficacy before being authorised for use. Each batch of Tivacoma is manufactured under Good Manufacturing Practice (GMP) standards, which set strict requirements for sterility, identity, strength, and purity of the finished product. The pre-filled syringe presentation also includes integrity controls that allow the patient or healthcare professional to detect tampering or visible defects before injection.
Tivacoma is intended for use under medical supervision. Even in cases where the patient or a caregiver administers the injection at home, the prescriber remains responsible for selecting the indication, choosing the dose and dosing interval, monitoring response and tolerability, and adjusting therapy when necessary. Do not use Tivacoma for any condition other than the one for which it was prescribed, and do not share the medication with another person, even if their symptoms appear similar to your own.
Tivacoma is supplied as a single-use, pre-filled syringe. Never reuse a syringe, never share it with another person, and never inject Tivacoma without being trained in correct subcutaneous injection technique. If you are unsure how to give yourself the injection, contact your prescriber, nurse, or pharmacist for further training before continuing treatment.
What Should You Know Before Using Tivacoma?
Before starting Tivacoma, tell your healthcare provider about every medical condition you have, every medication or supplement you take, and any allergies, including any prior reaction to injectable products. Certain conditions require additional monitoring or a modified dosing approach. Your prescriber will assess whether Tivacoma is suitable for you and whether self-administration is appropriate.
Contraindications
Do not use Tivacoma if you are hypersensitive (allergic) to the active substance tivacoma or to any of the excipients listed in the patient information leaflet supplied with the syringe. Hypersensitivity to injectable medicinal products may present as itching or rash at the injection site, generalised urticaria, swelling of the lips, tongue, or throat (angioedema), bronchospasm, or anaphylactic shock. If you have ever experienced a severe allergic reaction to a related compound, inform your doctor before the first dose so an alternative therapy can be considered.
Tivacoma should not be administered into skin that is broken, bruised, scarred, infected, inflamed, or affected by an active dermatological condition such as eczema or psoriasis. Injection into compromised skin can increase the risk of local infection, slow absorption, or aggravate the underlying skin condition. Choose only intact skin areas, and if you cannot find a suitable injection site, contact your prescriber for guidance.
If you have an active systemic infection, your prescriber may decide to delay starting Tivacoma until the infection has resolved. Untreated infection at the time of starting an injectable therapy can mask early signs of treatment-related adverse events and may worsen with concurrent treatment. Always tell your healthcare team about ongoing infections, recent hospitalisations, or recent invasive procedures before each appointment.
Warnings and Precautions
Talk to your doctor, nurse, or pharmacist before starting Tivacoma if any of the following apply to you:
- Liver disease: Hepatic impairment can alter the metabolism of many medications. Your prescriber may order baseline liver function tests and arrange periodic monitoring during treatment.
- Kidney disease: Reduced renal function may affect the elimination of the medication or its metabolites. Dose or dosing-interval adjustment may be required, especially in moderate to severe renal impairment.
- Bleeding disorders or anticoagulant therapy: Subcutaneous injections can produce small bruises or haematomas. Patients on warfarin, direct oral anticoagulants, antiplatelet agents, or with conditions such as haemophilia may experience more pronounced injection-site bleeding and should apply gentle pressure after the injection.
- Cardiovascular disease: Disclose any history of heart failure, ischaemic heart disease, arrhythmia, or stroke so that your prescriber can monitor for treatment-emergent symptoms.
- Immune system disorders: Tell your prescriber about autoimmune conditions, immunodeficiency, recent vaccinations (especially with live vaccines), and any planned surgery.
- Older adults: Patients aged 65 years and over may be more susceptible to adverse effects due to age-related changes in organ function and a higher prevalence of comorbidities.
Your prescriber may schedule regular reviews while you are receiving Tivacoma. These reviews typically include an assessment of treatment response, tolerability, injection-site appearance, and any new or worsening symptoms. Laboratory tests — for example complete blood count, liver enzymes, or renal function — may be ordered at intervals appropriate for your clinical situation. Attend all scheduled appointments and bring an up-to-date list of all medicines you are taking.
If you are scheduled for surgery or any invasive procedure, tell the treating team that you are receiving Tivacoma. Depending on the type and timing of the procedure, your specialist may advise a temporary pause in treatment to reduce the risk of bleeding or infection, and provide guidance on when to restart Tivacoma after the intervention.
Tivacoma is generally not expected to impair your ability to drive or use machines. However, if you experience dizziness, fatigue, headache, or visual disturbances after an injection, do not drive or operate machinery until those symptoms have resolved.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, are planning a pregnancy, or are breastfeeding, discuss this with your prescriber before initiating or continuing Tivacoma. The decision to use any prescription injectable during pregnancy must balance the potential benefit to the patient against any theoretical or known risk to the developing fetus, particularly in the first trimester when major organ systems are forming.
It is not always known whether the active substance in an injectable medication crosses into breast milk in clinically meaningful concentrations. If you are breastfeeding, your prescriber will weigh the importance of Tivacoma for your own health against the potential exposure of your nursing infant. In some cases, your specialist may recommend pausing breastfeeding during treatment, switching to an alternative therapy, or proceeding with treatment under careful infant monitoring.
Women of childbearing potential who are using Tivacoma should discuss reliable contraception with their healthcare provider, both during treatment and for a defined period after the final dose, in line with the prescriber's specific guidance. If you become pregnant during treatment, contact your prescriber as soon as possible so that the treatment plan can be reviewed and any necessary monitoring arranged.
Do not start, stop, or change the timing of Tivacoma injections without consulting your prescribing physician. If you are pregnant or breastfeeding, your prescriber will assess the individual risk-benefit ratio before treatment decisions are made, and may involve specialist obstetric or paediatric input.
How Does Tivacoma Interact with Other Drugs?
Tivacoma can interact with several other medications, vaccines, and biological agents. Always provide your prescriber and pharmacist with a complete and current list of all prescription drugs, over-the-counter medications, vitamins, dietary supplements, and herbal products that you are taking. Some interactions require dose adjustment or extra monitoring, while others should be avoided entirely.
Drug interactions are clinically significant changes in the effect of a medication that result from concurrent use of another agent. They can be broadly divided into pharmacokinetic interactions (affecting absorption, distribution, metabolism, or elimination) and pharmacodynamic interactions (resulting from additive, synergistic, or antagonistic effects on the same physiological system). The likelihood and severity of an interaction depend on the specific agents involved, the doses used, the timing of administration, and individual patient characteristics such as age, organ function, and genetic factors.
Pharmacokinetic interactions involving an injectable like Tivacoma are typically related to the metabolism or elimination of the active substance once it has reached the systemic circulation. Other medications that induce or inhibit hepatic enzymes — particularly the cytochrome P450 system — may alter the systemic exposure to tivacoma. Injectable medications can also be affected by changes in plasma protein binding when several highly protein-bound drugs are co-administered.
Pharmacodynamic interactions are particularly relevant when Tivacoma is co-administered with medications that act on overlapping target systems, such as anticoagulants (which may compound bleeding-related adverse events), other immunomodulating therapies (which may have additive effects on infection risk), or central nervous system depressants (which may potentiate fatigue, dizziness, or sedation reported with some injectables).
Vaccinations deserve special attention. If you receive Tivacoma, ask your prescriber whether live vaccines (for example yellow fever, oral polio, BCG, or live attenuated influenza vaccine) are appropriate for you. In some cases live vaccines should be avoided or scheduled at a specific interval before or after Tivacoma. Inactivated vaccines are usually compatible, although the immune response may be modified depending on the underlying condition and treatment regimen.
Potential Drug Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance | Recommendation |
|---|---|---|---|
| CYP450 enzyme inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) | Pharmacokinetic | May raise systemic exposure to tivacoma and increase the risk of dose-related side effects | Monitor closely; the prescriber may consider a dose reduction or extended dosing interval |
| CYP450 enzyme inducers (e.g., rifampicin, phenytoin, carbamazepine) | Pharmacokinetic | May reduce systemic exposure and lessen therapeutic effect of Tivacoma | Consult prescriber; alternative therapy or dose modification may be required |
| Anticoagulants (warfarin, DOACs, low molecular weight heparin) | Pharmacodynamic | Increased risk of injection-site bruising and bleeding events | Apply firm pressure after injection; monitor for unusual bruising or bleeding |
| Antiplatelet agents (aspirin, clopidogrel, ticagrelor) | Pharmacodynamic | May enhance bleeding tendency at the injection site | Continue under medical supervision; report unusual bruising |
| Live attenuated vaccines | Immunological | Theoretical risk of disseminated infection in some patient groups | Discuss vaccination plans with prescriber before administration |
| Other immunomodulators or biologics | Pharmacodynamic | Possible additive effects on the immune system, including increased infection risk | Combination only under specialist supervision with active monitoring |
| Herbal supplements (e.g., St John's Wort) | Pharmacokinetic | May lower the systemic concentration of tivacoma via enzyme induction | Avoid concurrent use unless approved by your prescriber |
The interactions listed above are illustrative and not exhaustive. Many other agents may potentially interact with Tivacoma. Always carry an up-to-date list of every medicine, supplement, and herbal product you take, and share it at every clinical encounter, including emergency-department visits and dental appointments. This single habit prevents a substantial proportion of avoidable drug-related harm.
Ask your prescriber whether alcohol consumption is acceptable while you are using Tivacoma. Alcohol can affect liver enzyme activity, may worsen fatigue or dizziness, and can interact with concomitant medications. Personalised advice depends on your full medication list and any underlying liver, neurological, or psychiatric conditions.
What Is the Correct Dosage of Tivacoma?
Tivacoma is supplied as a 30 mg pre-filled syringe for subcutaneous injection. The exact dose, dosing interval, and total duration of treatment are decided by your prescriber based on the indication, your weight, organ function, comorbidities, and clinical response. Always follow the dosing schedule provided by your healthcare team and never change the dose on your own.
The correct dose of Tivacoma is highly individual. Factors that influence dose selection include the diagnosis being treated, disease severity, body weight, hepatic and renal function, age, and concurrent medications. After the first dose, your prescriber will assess how you have responded to treatment and may adjust the dose, the dosing interval, or both. Do not increase, decrease, or skip a scheduled injection without explicit medical advice.
Adults
Standard Adult Dosage
The typical formulation is one 30 mg pre-filled syringe per administration, given subcutaneously according to the schedule prescribed by your physician. Common subcutaneous schedules include weekly, every two weeks, or monthly dosing, but the exact interval depends on the specific indication and the prescriber's clinical judgement. The injection should be given at the same time of day on the scheduled days to keep the dosing interval as consistent as possible.
If your prescriber adjusts your dose — for example by changing the dosing interval — the new schedule should be written down and confirmed with your nurse or pharmacist. Bring an updated treatment plan to every clinical visit.
Children and Adolescents
Paediatric Use
The safety and efficacy of Tivacoma in children and adolescents under 18 years of age have not been established for general use. Tivacoma should not be administered to a paediatric patient unless a specialist physician has carefully assessed the benefit-risk balance and has decided that treatment is appropriate. If a child does receive Tivacoma, the dose, injection technique, and monitoring schedule must be adapted by the prescribing specialist, and a parent or caregiver should be formally trained in safe handling and administration.
Elderly Patients
Geriatric Dosage Considerations
Older adults may have age-related reductions in renal and hepatic function, a higher prevalence of cardiovascular disease, and a greater number of concomitant medications. These factors can increase the risk of side effects from any prescription injectable. The prescriber may begin treatment at the lower end of the dosing range, monitor more frequently, and increase the dose only after assessing tolerability. Caregivers of older patients should be alert to falls, confusion, fatigue, and any new symptoms after the injection.
Correct Injection Technique
How to Give a Subcutaneous Injection of Tivacoma
Subcutaneous injection means injecting the medication into the layer of fatty tissue just below the skin. Patients and caregivers must receive structured training before self-administering Tivacoma. The general procedure is as follows:
- Take the pre-filled syringe out of the refrigerator and let it reach room temperature for approximately 30 minutes — do not warm it with hot water, a microwave, or any external heat source.
- Inspect the solution. It should be clear to slightly opalescent and free from visible particles. If the solution is discoloured or contains particles, do not inject and contact your pharmacist.
- Wash your hands thoroughly with soap and water.
- Choose an injection site — usually the abdomen (at least 5 cm away from the navel) or the front of the thigh. Avoid bruised, tender, hard, red, or scarred skin.
- Clean the chosen site with an alcohol swab and let it dry.
- Remove the needle cap. Do not touch the needle or place it on any surface.
- Pinch a fold of skin and insert the needle at the angle recommended in your training (typically 45° to 90°).
- Press the plunger slowly and steadily until the syringe is empty.
- Withdraw the needle, release the skin fold, and apply gentle pressure with a cotton ball — do not rub.
- Place the used syringe in an approved sharps container immediately. Never recap the needle.
Rotate injection sites with each dose to reduce the risk of skin thickening, lipodystrophy, or persistent local reactions. If you experience pain, redness, or swelling at an injection site that does not resolve within a few days, contact your healthcare provider.
Missed Dose
If you miss a scheduled dose of Tivacoma, do not give yourself two injections to make up for it. Contact your prescriber, nurse, or pharmacist as soon as possible for guidance. The recommended action depends on how late the dose is and the prescribed dosing interval. In some cases the missed dose can be administered immediately, after which the schedule resumes from that point; in other cases the next dose simply continues at the originally planned time.
To reduce the chance of forgetting a dose, consider keeping a treatment diary, setting calendar alerts, or asking a family member or caregiver to remind you. If you frequently miss doses because of side effects or practical difficulties (for example pain at the injection site, anxiety about self-injection, or travel), discuss this with your prescriber so that adjustments can be made.
Overdose
If a higher dose of Tivacoma than prescribed has been administered, or if more than one syringe has been injected accidentally, contact your local poison control centre or attend the nearest emergency department immediately. Bring the original carton, syringe, and patient information leaflet so that medical staff can identify the product, the strength, and the exact amount that was given. Symptoms of overdose may include exaggerated forms of the known side effects (for example marked fatigue, nausea, dizziness, or pronounced injection-site reactions). Treatment is supportive and tailored to the symptoms observed.
| Patient Group | Starting Dose | Notes |
|---|---|---|
| Adults | 30 mg pre-filled syringe (as directed) | Dose, dosing interval, and total duration determined by prescribing physician |
| Elderly (≥65 years) | May start at lower end of dosing range | Adjust based on renal/hepatic function; monitor frequently for adverse events |
| Children (<18 years) | Not established | Use only under specialist paediatric supervision |
| Renal impairment | May require dose or interval adjustment | Monitor renal function before and during treatment |
| Hepatic impairment | May require dose or interval adjustment | Monitor liver function and clinical signs of hepatotoxicity |
| Pregnancy / breastfeeding | Use only if benefit outweighs risk | Specialist obstetric input strongly recommended |
What Are the Side Effects of Tivacoma?
Like all medicines, Tivacoma can cause side effects, although not everyone gets them. Many side effects are mild and short-lived, particularly local injection-site reactions. Contact your prescriber promptly if you develop a severe injection-site reaction, signs of infection, or symptoms suggestive of an allergic reaction.
Side effects of injectable medications can be divided into local reactions at the injection site and systemic effects involving the rest of the body. They are usually classified by frequency: very common (more than 1 in 10 people), common (1 in 10 to 1 in 100), uncommon (1 in 100 to 1 in 1,000), and rare (fewer than 1 in 1,000). The exact frequency profile for any individual product is described in the most recent Summary of Product Characteristics.
Allergic reactions deserve particular attention with any injectable medication. Signs of a serious allergic reaction include sudden swelling of the face, lips, tongue or throat (angioedema); generalised hives; tightness in the chest; wheezing or difficulty breathing; rapid heartbeat; or feeling faint. These symptoms can develop rapidly — sometimes within minutes of an injection — and constitute a medical emergency. If they occur, call your local emergency number or attend the nearest emergency department immediately.
Most side effects of subcutaneous injectables are mild and improve as treatment continues. However, persistent, worsening, or severe side effects should always be discussed with your prescriber, who can decide whether to adjust the dose, treat the side effect symptomatically, or change therapy. Keeping a simple symptom diary — noting the date, location, and nature of any reaction — can be very helpful at follow-up visits.
Very Common Side Effects
May affect more than 1 in 10 people
- Injection-site reactions: redness, swelling, mild pain, itching, or bruising at the puncture site
- Headache
- Mild fatigue, particularly within the first 24 hours after injection
Common Side Effects
May affect up to 1 in 10 people
- Nausea
- Dizziness
- Mild upper respiratory tract symptoms (runny nose, sore throat)
- Localised induration (small lump) at the injection site
- Low-grade fever during the first 24 hours after injection
- Muscle or joint discomfort
Uncommon Side Effects
May affect up to 1 in 100 people
- Skin rash beyond the injection site
- Diarrhoea or constipation
- Insomnia or vivid dreams
- Mood changes such as low mood or irritability
- Mild changes in blood cell counts on routine laboratory testing
- Transient elevation of liver enzymes
Rare Side Effects
May affect up to 1 in 1,000 people
- Severe hypersensitivity reaction (anaphylaxis)
- Persistent or progressive injection-site infection
- Significant changes in blood pressure or heart rate
- Visual disturbances
- Clinically significant changes in liver or kidney function tests
Sudden swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; severe rash with blistering or peeling; high fever with chills; severe pain, spreading redness, or pus at the injection site; fast or irregular heartbeat; or feeling faint shortly after an injection. These symptoms may indicate a serious adverse event such as anaphylaxis or injection-site infection and require emergency assessment.
You are encouraged to report any suspected adverse reactions to your prescriber and to your national pharmacovigilance authority (for example, the EU EudraVigilance system, the UK Yellow Card Scheme, or the US FDA MedWatch programme). Spontaneous reporting helps regulators identify previously unknown safety signals and improves the safety information available to all patients. Reports should include the medication name, batch number (printed on the syringe label and carton), dose, dosing date, suspected reaction, and the outcome.
How Should You Store Tivacoma?
Store Tivacoma pre-filled syringes in a refrigerator at 2°C–8°C (36°F–46°F) in the original carton to protect them from light. Do not freeze. Do not shake. Allow the syringe to reach room temperature for about 30 minutes before injection. Keep all medicines out of the reach and sight of children.
Tivacoma is a cold-chain medicinal product, meaning it must be kept refrigerated continuously from the manufacturer to the moment of use. Store the syringes in the original carton on a middle shelf of the refrigerator — not in the door (where temperature fluctuates with each opening) and not against the back wall (where they could accidentally freeze). The recommended temperature range is 2°C to 8°C. If you suspect that a syringe has been frozen at any point, do not use it; contact your pharmacist for advice on disposal and replacement.
Do not shake the syringe. Excessive agitation of an aqueous protein or peptide solution can produce visible particles or fine foam, which may indicate that the medication is no longer suitable for injection. The syringe should always be inspected before use: the solution should appear clear to slightly opalescent and free from visible particles. If you are unsure about the appearance, contact your pharmacist before injecting.
Allow the syringe to reach room temperature for approximately 30 minutes before administration. Injecting cold solution can be uncomfortable and may slow absorption. Do not warm the syringe with a microwave, hot water, or any direct heat source — warming above the recommended temperature can damage the active substance. Simply place the syringe (still in its original packaging) at normal room temperature for the recommended time.
If you need to travel with Tivacoma, plan ahead. Use a medical-grade insulated cool bag with frozen gel packs, ensuring the syringe does not come into direct contact with the ice packs to prevent freezing. Carry a copy of your prescription and a brief letter from your prescriber when crossing international borders. For air travel, request that your medication be kept in cabin baggage rather than the hold, where temperatures can drop below freezing.
Do not use Tivacoma after the expiry date printed on the carton and the syringe label. The expiry date refers to the last day of the stated month. Expired medications may have reduced potency, altered solubility, or unpredictable safety profiles. Used and expired syringes must be discarded into an approved sharps container; do not throw them in household rubbish or recycle them. Many community pharmacies operate sharps return programmes — ask your pharmacist for the local arrangements.
Place every used syringe immediately into a puncture-resistant sharps container. Do not recap the needle, do not snap or bend the needle, and do not place loose syringes in the household waste. Once the sharps container is three-quarters full, return it to your pharmacy or designated collection point for safe disposal. Unused or expired syringes should also be returned to the pharmacy — never flush medications down the toilet or pour them down the sink, as this can contaminate the environment.
What Does Tivacoma Contain?
Each Tivacoma pre-filled syringe contains 30 mg of the active substance tivacoma in a sterile aqueous solution suitable for subcutaneous injection. The solution also contains pharmaceutical excipients selected to maintain stability, isotonicity, and appropriate pH for parenteral use.
The active ingredient in each pre-filled syringe is tivacoma 30 mg. This is the substance responsible for the therapeutic effect of the product. The strength has been chosen on the basis of pharmacokinetic and clinical data so that a single subcutaneous injection delivers a measured systemic dose with predictable absorption.
In addition to the active substance, Tivacoma contains a small number of inactive ingredients (excipients) that perform critical pharmaceutical functions. Common excipients in subcutaneous solutions include a buffer system to maintain the correct pH (often based on phosphate, histidine, or acetate), a tonicity agent (such as sodium chloride or sucrose) to keep the solution iso-osmolar with body tissue, a stabiliser (for example a non-ionic surfactant like polysorbate 20 or 80) to prevent aggregation, and water for injection as the solvent. The specific composition for your batch is listed in the patient information leaflet supplied with the syringe.
If you have a known allergy or intolerance to a particular pharmaceutical excipient — for example to polysorbates or to specific buffer components — tell your prescriber and pharmacist before starting Tivacoma. They can verify the full excipient list against your allergy history and advise on the safest course of action. Hypersensitivity to an excipient can sometimes mimic an allergic reaction to the active substance and may be missed without a careful history.
The pre-filled syringe itself is a medical device that has been validated for use with the Tivacoma solution. The syringe barrel, plunger, and needle are designed to deliver the labelled dose accurately and to maintain sterility until the moment of use. Some pre-filled syringes include passive needle-protection devices to reduce the risk of needlestick injury after administration. Always follow the device-specific instructions provided with your syringe and confirm any unfamiliar features with your pharmacist or nurse.
Frequently Asked Questions About Tivacoma
Tivacoma is a prescription-only injectable medication supplied as a single-use 30 mg pre-filled syringe containing the active substance tivacoma. It is administered as a subcutaneous injection. Your prescriber will decide whether Tivacoma is appropriate for your specific medical condition, choose the dosing schedule, and review your response to treatment. Always follow the indication and dosing instructions provided in your individual treatment plan.
Tivacoma is given as a subcutaneous injection — just under the skin — either by a healthcare professional or by a patient or caregiver who has completed structured injection-technique training. Common injection sites include the abdomen (at least 5 cm from the navel) and the front of the thigh. Allow the syringe to warm to room temperature for about 30 minutes, inspect the solution, clean the chosen site, inject as taught, and discard the used syringe immediately into an approved sharps container. Rotate sites with each injection.
If you miss a scheduled dose of Tivacoma, do not give yourself two injections to compensate. Contact your prescriber, nurse, or pharmacist as soon as possible for personalised advice. The correct action depends on how late the dose is and on the prescribed dosing interval. To prevent missed doses in the future, consider using a calendar reminder, treatment diary, or smartphone app, and ask a family member or caregiver to help you stay on schedule.
Discuss alcohol consumption with your prescriber. Alcohol can affect liver enzyme activity, potentially altering the metabolism of Tivacoma and other medications, and may aggravate side effects such as fatigue, dizziness, or nausea. Personalised advice depends on your overall medication list and any underlying liver, neurological, or psychiatric conditions. Avoid alcohol if your prescriber advises against it during treatment.
No, Tivacoma is classified as a prescription-only medication (Rx). It can only be supplied with a valid prescription from a licensed healthcare professional. Treatment is usually initiated by a specialist physician with experience in the relevant clinical area, and patients or caregivers receive structured injection-technique training before any home-administered doses. The prescription requirement also ensures appropriate ongoing monitoring of effectiveness, side effects, and laboratory parameters.
Store unopened Tivacoma syringes in a refrigerator at 2°C–8°C (36°F–46°F), in the original carton to protect them from light. Do not freeze and do not shake. Place the carton on a middle shelf rather than in the refrigerator door. Allow the syringe to reach room temperature for about 30 minutes before injection — never warm it with a microwave or hot water. Keep the medication out of the reach and sight of children, and do not use the syringe after the expiry date printed on the label and carton.
Mild redness, slight swelling, itching, or bruising at the injection site is common and usually resolves within a few days. Applying a cold compress for short periods can help reduce discomfort. However, contact your healthcare provider if a reaction is severe, spreading, very painful, accompanied by warmth and pus (suggesting infection), or persists beyond a few days. Consistently rotating injection sites and using correct injection technique substantially reduce the risk of recurrent local reactions.
Always discuss any planned vaccination with your prescriber before having it. Inactivated vaccines (for example most seasonal influenza vaccines, the COVID-19 mRNA vaccines, and the standard tetanus booster) are generally compatible with treatment, although the immune response may be modified depending on your underlying condition. Live attenuated vaccines (such as yellow fever, oral polio, BCG, MMR, or varicella) may be inadvisable for some patients during treatment and should be timed carefully. Tell every healthcare professional involved in your care that you are receiving Tivacoma.
References and Sources
This article is based on internationally recognised medical and pharmaceutical guidelines. All information has been reviewed by qualified healthcare professionals and follows evidence-based principles.
- European Medicines Agency (EMA). Guideline on Summary of Product Characteristics (SmPC). EMA, 2024. Available at: www.ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization, 2023.
- British National Formulary (BNF). Prescribing Guidance: Drug Interactions, Subcutaneous Injection Technique and Side Effects. NICE, 2024. Available at: bnf.nice.org.uk
- U.S. Food and Drug Administration (FDA). Drug Safety Communications and Labeling Changes — Injectable Products. FDA, 2024. Available at: www.fda.gov
- Goodman & Gilman's. The Pharmacological Basis of Therapeutics. 14th Edition. McGraw-Hill Education, 2023.
- European Pharmacopoeia Commission. European Pharmacopoeia, 11th Edition — Monograph on Parenteral Preparations. Council of Europe, 2023.
- International Council for Harmonisation (ICH). ICH E2C(R2): Periodic Benefit-Risk Evaluation Report. ICH, 2023.
- World Health Organization (WHO). WHO Best Practices for Injections and Related Procedures Toolkit. Geneva: World Health Organization, 2010.
- European Centre for Disease Prevention and Control (ECDC). Vaccination Recommendations in Patients on Immunomodulating Therapy. ECDC, 2024.
About the Medical Editorial Team
This article has been written and reviewed by iMedic's Medical Editorial Team, consisting of licensed physicians and specialists in clinical pharmacology with expertise in injectable therapeutics, drug safety, pharmacovigilance, and evidence-based medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology, parenteral medications, and patient drug information. All content is researched and written using peer-reviewed sources and international pharmaceutical guidelines.
iMedic Medical Review Board – independent panel of qualified physicians who review all drug information content for accuracy, completeness, and clinical relevance according to EMA, FDA, and WHO standards.
Editorial Standards: All pharmaceutical content on iMedic follows strict editorial standards based on the GRADE evidence framework. We do not accept any form of pharmaceutical industry sponsorship or advertising. Our content is independent, evidence-based, and written for patients and caregivers. Read more about our editorial standards.